Research
Original data & PubMed-cited science on GLP-1 weight loss.
We track every major GLP-1 telehealth provider in the United States and publish two kinds of long-form pieces: data investigations using our live dataset, and PubMed-cited scientific deep-dives on the studies that actually matter. Both update as the underlying data changes.
Research formats
Related tools
- Data investigation8 min · 3 sources
GLP-1 Telehealth Cancellation Index 2026
Some GLP-1 telehealth programs are month-to-month with no strings; others bury a membership fee, a multi-month prepay, or a remaining-balance charge in the fine print. We pulled the cancellation, commitment, and refund terms from each provider's own site into one index — cancel-anytime vs locked-in — updated live as our dataset changes, with CSV/JSON downloads.
Read the analysis→ - Data investigation10 min · 2 sources
Medicaid GLP-1 Spending by State (2019–2026)
We aggregated the CMS State Drug Utilization Data into a state-by-state tracker of Medicaid GLP-1 spending and prescriptions from 2019 to 2026. US Medicaid spent about $8.8 billion (gross) on GLP-1s in 2024, led by Ozempic at $3.4 billion. The 2026 coverage cliff is already visible: after Pennsylvania dropped obesity-drug coverage on January 1, quarterly Wegovy prescriptions collapsed 96%, and California fell 76%. Full downloadable dataset inside.
Read the analysis→ - Data investigation9 min · 3 sources
GLP-1 & Weight Loss Care Access by State (2026)
We cross-referenced the CMS NPPES registry, US Census population estimates, and our verified telehealth provider dataset to map GLP-1 care access across all 50 states and DC. Maryland leads with 18.15 clinics per 100,000 residents; Iowa trails at 5.24 — a ~3.5× gap that telehealth largely closes, since every state has 75+ verified telehealth options. Full downloadable dataset inside.
Read the analysis→ - Scientific deep-dive6 min · 2 sources
Metabolic Longevity: Do Anti-Aging Drugs & Supplements Actually Help Weight and Metabolism?
The wellness market sells a whole shelf of 'metabolic longevity' drugs and supplements as gentler alternatives to Ozempic — metformin, berberine, NAD, rapamycin, senolytics. Which actually help weight and metabolism? Ranked by human evidence: only GLP-1 agonists are proven (~15-21% in phase-3 trials); metformin is modest; berberine and NAD are weak or unproven for weight; rapamycin and senolytics are experimental and carry real risks. This hub ranks them honestly and links each to our fully-cited deep-dive.
Read the analysis→ - Scientific deep-dive9 min · 16 sources
Senolytics for Weight Loss & Metabolic Health: What the Evidence Actually Shows
Senolytics — drugs that clear 'zombie' senescent cells — are a genuine longevity research frontier, and senescent cells do accumulate in fat with obesity. But is there human evidence they cause weight loss or fix metabolism? No. The only obesity-metabolic benefit is a mouse finding; the human trials that exist are tiny safety pilots in kidney and lung disease that measured senescent-cell markers, not weight. This review covers what senolytics are, the animal-versus-human gap, the real trials, the safety caveats (dasatinib is a chemotherapy drug), and their unapproved status.
Read the analysis→ - Scientific deep-dive9 min · 11 sources
Rapamycin for Weight Loss & Metabolic Health: What the Evidence Actually Shows
Rapamycin is a longevity darling — but is it a weight-loss or metabolic drug? The honest answer is no. There are zero human weight-loss RCTs, and chronic dosing can actually worsen blood sugar and lipids by disrupting mTORC2. It is an FDA-approved transplant immunosuppressant (Rapamune) with landmark mouse lifespan data but only small human healthspan trials, none measuring weight. This evidence review walks through the mechanism, the metabolic paradox, the animal-versus-human longevity gap, the safety profile, and why all weight and anti-aging use is off-label.
Read the analysis→ - Scientific deep-dive7 min · 5 sources
GLP-1 Pipeline Tracker: Every Next-Gen Weight-Loss Drug in Development (2026)
Wegovy and Zepbound are not the finish line. This living tracker maps the next-gen GLP-1 and incretin pipeline in one table: which compounds are in development, how far along each is, and the peak weight loss reported. Orforglipron (Foundayo) is FDA-approved, retatrutide and CagriSema lead the phase-3 pack at roughly 24% and 22.7%, and Pfizer's danuglipron was discontinued. Cross-trial comparisons are unreliable and only orforglipron is FDA-approved for weight loss; every row links to our full, individually-cited guide.
Read the analysis→ - Scientific deep-dive10 min · 27 sources
GLP-1 Weight-Loss Trial Results: The Complete Database (STEP, SURMOUNT & Every Major Trial)
The one reference table for the major GLP-1 trials. Weight-loss results plus the organ-outcome trials (heart, kidney, liver, sleep apnea, knee) for every approved drug — semaglutide, tirzepatide, orforglipron, liraglutide — with N, duration, dose, and primary endpoint, each sourced to its peer-reviewed publication and verified against PubMed. Tirzepatide leads on weight (~20.9%, and beat semaglutide head-to-head); the organ-protection trials are now the strongest part of the class. Cross-trial comparisons are unreliable — read the caveats, then use the table as your map.
Read the analysis→ - Scientific deep-dive9 min · 6 sources
Is Compounded Semaglutide & Tirzepatide Legal in Your State? (2026 Tracker)
Searching whether compounded semaglutide or tirzepatide is legal in your state turns up dozens of pages that all say the same thing — because the rules are almost entirely federal. This tracker gives the part that actually matters: the national timeline of what changed and when (with drug-specific 2025 deadlines and the still-pending May 2026 503B proposal), the personalized-compounding door that remains open in every state, the few states that added their own guidance or enforcement, and how telehealth shipping works across state lines. Every state entry is sourced to a primary document.
Read the analysis→ - Scientific deep-dive8 min · 4 sources
Compounded Semaglutide & Tirzepatide Are Going Away: Your 2026 Options
Getting compounded semaglutide or tirzepatide for $100-250/mo? The ground has shifted. The FDA shortages that made mass compounding legal ended in 2025, and in May 2026 the FDA proposed permanently barring outsourcing facilities from compounding these drugs — though that rule is still pending, not a ban. This honest decision guide separates what already happened from what is only proposed, and walks through the four real options: switch to brand at the new lower direct-pay prices, switch to the oral pill, taper off (with eyes open about weight regain), or avoid the gray market. Links to our cost, switching, and compounded-vs-brand deep-dives for the numbers.
Read the analysis→ - Scientific deep-dive8 min · 3 sources
TRICARE GLP-1 Prior Authorization Guide: Military Weight-Loss Coverage for Wegovy, Zepbound, and Saxenda (2026)
Unlike Medicare, TRICARE covers weight-management GLP-1s (Wegovy, Zepbound, Saxenda) with an approved prior authorization, but only for TRICARE Prime, TRICARE Select, and premium-based plans, and Saxenda also requires a medical-necessity form. As of August 31, 2025, weight-loss drug coverage ended for TRICARE For Life, direct-care-only, and NATO / Partnership-for-Peace beneficiaries, who now pay 100% even with an approved PA. Diabetes GLP-1s remain covered for all plans for type 2 diabetes. All weight-loss agents need a PA, a TRICARE-authorized prescriber, and a network pharmacy; initial PA is 12 months, renewal needs 5% baseline weight loss (adults) or 4% (adolescents). Denials get a written appeal to Express Scripts within 90 calendar days.
Read the analysis→ - Scientific deep-dive8 min · 2 sources
Blue Cross Blue Shield GLP-1 Coverage Guide: Why Weight-Loss Coverage Varies by State Plan (2026)
There is no single Blue Cross Blue Shield GLP-1 policy to look up. BCBS is a federation of about 34 independent licensees, and weight-loss GLP-1 coverage is set plan-by-plan and often employer-by-employer. GLP-1s for type 2 diabetes stay widely covered, while obesity GLP-1s (Wegovy, Zepbound, Saxenda) are being restricted or excluded through 2025-2026. BCBS of Massachusetts covers GLP-1s only for type 2 diabetes effective January 1, 2026, a benefit exclusion that cannot be appealed. BCBS of Michigan excludes Wegovy, Zepbound, and Saxenda for weight loss for large-group fully-insured members. Where coverage remains, PA typically requires BMI 30+ (or 27+ with a comorbidity), documented lifestyle participation, and 5% weight loss for reauthorization.
Read the analysis→ - Scientific deep-dive9 min · 3 sources
Humana GLP-1 Prior Authorization Guide: Medicare Part D Coverage, the Weight-Loss Exclusion, and the $50 Medicare GLP-1 Bridge (2026)
Humana is primarily a Medicare insurer, and Medicare Part D is barred by federal statute from covering agents used for weight loss, so a standard Humana Part D or MAPD plan will not cover Wegovy, Zepbound, or Saxenda for obesity alone. Humana does cover GLP-1s under Part D with prior authorization for a covered non-obesity indication: type 2 diabetes, cardiovascular-risk reduction (Wegovy), or moderate-to-severe obstructive sleep apnea (Zepbound). Beginning July 1, 2026, eligible Part D members can get Foundayo, all Wegovy formulations, or the Zepbound KwikPen for weight loss at a flat $50 copay through the temporary Medicare GLP-1 Bridge, which runs through December 31, 2027 and sits outside the Part D benefit. CMS selected Humana to administer the Bridge nationwide for every Part D plan.
Read the analysis→ - Scientific deep-dive8 min · 1 sources
Kaiser Permanente GLP-1 Prior Authorization & Coverage Guide: What Kaiser Covers for Weight Loss After the January 2025 Change (2026)
Kaiser Permanente covers GLP-1s for a disease indication (type 2 diabetes: Ozempic, Mounjaro, Trulicity) but as of January 2025 does not cover GLP-1s for weight loss alone under base coverage. Where weight-management coverage remains, Wegovy, Saxenda, and Zepbound need PA with a BMI gate, phentermine/Qsymia/Contrave step therapy, mandatory lifestyle-program enrollment, a 16-week Zepbound washout, and 5% weight loss to reauthorize. Kaiser is an integrated HMO, so PA and appeals run internally; the California external step is a free DMHC Independent Medical Review.
Read the analysis→ - Scientific deep-dive8 min · 3 sources
Oscar Health GLP-1 Coverage & Prior Authorization Guide: The PG070 Pathway Most Plans Don't Include (2026)
Oscar Health is one of the few ACA Marketplace insurers that keeps a genuine clinical pathway to cover GLP-1s for weight loss: guideline PG070 names Wegovy, Saxenda, and Zepbound as agents that can be approved with prior authorization. But the pathway only applies to members whose plan covers anti-obesity drugs, coverage varies by benefit policy, and most Oscar Marketplace plans exclude weight-loss drugs — so obesity coverage is uncommon. Adult initial criteria: BMI 30+, or 27+ with a weight-related comorbidity, documented within the past month, used as an adjunct to diet and exercise. Reauthorization (up to 6 months) requires continued lifestyle modification plus 5% baseline weight loss. Diabetes GLP-1s run under a separate guideline (PG152). Denials follow the ACA framework: internal appeal to Oscar (or EviCore on delegated reviews), then external independent review.
Read the analysis→ - Scientific deep-dive8 min · 4 sources
Ambetter (Centene) GLP-1 Coverage & Prior Authorization Guide: Why Weight-Loss GLP-1s Are Excluded (2026)
Ambetter and Centene/Wellcare plans do not cover Wegovy, Zepbound, or Saxenda for weight management — Centene's clinical policy CP.PMN.295 states that using Wegovy for weight management is a benefit exclusion that will not be authorized. GLP-1s are covered with prior authorization only for non-obesity FDA indications: type 2 diabetes (with step therapy through Ozempic/Rybelsus, Trulicity, and generic liraglutide), semaglutide for cardiovascular risk reduction, and Wegovy for MASH. Ambetter is state-specific, and Wellcare Medicare follows the federal Part D weight-loss exclusion. Here is the policy language, the covered non-obesity pathways, and how to file an internal appeal within 180 days followed by external review.
Read the analysis→ - Scientific deep-dive8 min · 3 sources
Molina Healthcare GLP-1 Coverage & Prior-Authorization Guide (2026)
For most Molina members, weight-loss GLP-1s are an explicit benefit exclusion. Molina's own drug policy states Wegovy is a benefit exclusion for all indications in states that adopt the federal weight-loss-drug exclusion, and that such exclusions cannot be approved by formulary exception. Molina Medicare Part D cannot cover Wegovy, Zepbound, or Saxenda for weight loss by statute. Coverage exists only in a narrow set of markets (California and New Mexico Marketplace, plus the roughly 13 opt-in Medicaid states) and only with prior authorization for medically necessary treatment of morbid obesity. Diabetes GLP-1s (Ozempic, Mounjaro) remain covered under the diabetes benefit. Here is the verbatim policy language, the PA criteria where coverage exists, and the Medicaid managed-care appeal path.
Read the analysis→ - Scientific deep-dive8 min · 4 sources
Highmark GLP-1 Coverage & Prior-Authorization Guide (2026)
Highmark covers GLP-1 anti-obesity drugs — Wegovy, Saxenda, and plan-preferred Zepbound — for chronic weight management only when the member's specific plan includes an anti-obesity pharmacy benefit, and only through strict prior authorization. In late 2024 Highmark tightened its criteria dramatically: baseline BMI raised to 40 or higher plus comorbidity and metabolic requirements, step therapy through plan-preferred Zepbound, and a 7.5% weight-loss reauthorization gate. Many self-insured employer groups exclude the anti-obesity benefit entirely, so a member may have no coverage regardless of clinical criteria. Diabetes GLP-1s (Ozempic, Mounjaro) are unaffected. Here is the verbatim policy language, the PA criteria, and how to appeal within the 180-day window.
Read the analysis→ - Scientific deep-dive8 min · 4 sources
Health Net GLP-1 Coverage & Prior-Authorization Guide (2026)
Health Net's GLP-1 coverage splits by line of business. Under its Medi-Cal line (governed by California's Medi-Cal Rx), GLP-1s for weight loss — Wegovy, Zepbound, Saxenda — are no longer covered effective January 1, 2026, and previously approved prior authorizations ended December 31, 2025. Under Health Net's commercial large-group and Ambetter Marketplace plans, weight-loss GLP-1s can still be covered but with tightened criteria: prior authorization plus enrollment in a Health Net-approved weight-loss program, with BMI 40 or higher clearly eligible and BMI 30 to 40 dependent on the plan. Diabetes GLP-1s (Ozempic, Mounjaro) remain covered for type 2 diabetes with a diagnosis code. Here is the verbatim notice language, the PA criteria, and how to appeal.
Read the analysis→ - Scientific deep-dive8 min · 3 sources
CareSource GLP-1 Coverage & Prior-Authorization Guide (2026)
CareSource does not provide broad coverage of GLP-1s for weight management. Its Medicaid plans follow each state's rules — in Ohio, coverage runs through the state's Unified Preferred Drug List administered by Gainwell, not a CareSource formulary; in Michigan, HAP CareSource sharply reduced obesity-only GLP-1 coverage effective January 1, 2026. CareSource Medicare (Part D / D-SNP) is barred by federal statute from covering GLP-1s used solely for weight loss. GLP-1s for type 2 diabetes (Ozempic, Mounjaro) remain covered with prior authorization. Here is the verbatim policy language, the PA criteria where coverage exists, and the Medicaid managed-care appeal path.
Read the analysis→ - Scientific deep-dive13 min · 7 sources
Peptide Shots for Weight Loss: What the Evidence Actually Shows
Search 'peptide shots for weight loss' and you get two very different worlds bundled together. The peptides with real randomized evidence are the GLP-1s — semaglutide is a 31-amino-acid GLP-1 analogue (Lau 2015, PMID 26308095) that produced ~14.9% weight loss in STEP-1 (PMID 33567185), and tirzepatide (~20.9% in SURMOUNT-1, PMID 35658024; superior to semaglutide in SURMOUNT-5, PMID 40353578) is a 39-amino-acid peptide. So the 'weight loss shots' that work ARE peptide injections. Cagrilintide, an amylin analogue, is the one non-GLP-1 peptide with a credible human signal (~10.8% at 26 weeks, Lau 2021 Lancet phase 2, PMID 34798060) but is investigational. The 'research peptides' collapse under scrutiny: AOD-9604 lost weight in obese mice (PMID 11673763) but its human program was discontinued; BPC-157, CJC-1295/ipamorelin, and MOTS-c have no Phase 3 human weight-loss RCT. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy, not general obesity. 'Peptide' is not a quality signal — the evidence is.
Read the analysis→ - Scientific deep-dive12 min · 9 sources
Non-GLP-1 Weight Loss Shots: Do B12, Lipotropic (MIC) & HCG Work?
B12, lipotropic (MIC), and HCG are the injectables people confuse with the GLP-1 'weight loss shots' — and none causes weight loss on its own. B12 supplementation is ineffective for energy or weight in non-deficient adults (Markun 2021, 16 RCTs / 6,276 adults, PMID 33809274); it only matters when a real deficiency exists, as with long-term metformin (Aroda 2016 DPPOS, PMID 26900641) or vegan diets (Pawlak 2013, PMID 23356638). Lipotropic / MIC shots (methionine-inositol-choline) have no randomized trial showing fat loss — choline is a genuine essential nutrient in hepatic fat transport (NIH ODS) but that is not a weight-loss claim. HCG is not approved for weight loss: the FDA states the label carries 'no substantial evidence' of increased weight loss and that OTC HCG products are illegal, and Lijesen 1995 (PMID 8527285, Br J Clin Pharmacol) found it no better than placebo — the loss comes from the 500-cal diet. The shots with real evidence are the GLP-1s: semaglutide ~15% (STEP-1, PMID 33567185), tirzepatide ~21% (SURMOUNT-1, PMID 35658024).
Read the analysis→ - Scientific deep-dive9 min · 9 sources
Humanin: Mitochondrial-Derived Peptide Evidence Review
Humanin is a mitochondrial-derived peptide with compelling preclinical biology and human observational aging data, but zero randomized trials of administered humanin exist for any metabolic or longevity endpoint.
Read the analysis→ - Scientific deep-dive10 min · 10 sources
LL-37 Antimicrobial Peptide: Evidence and Double-Edged Biology
LL-37's endogenous biology is extensively documented, but injectable LL-37 has no human RCT, and its pro-inflammatory roles in rosacea, psoriasis, and certain cancers demand honest informed consent.
Read the analysis→
How we work
Every data point in our investigations is verified directly against provider websites, and the dataset updates continuously. Every scientific deep-dive cites primary literature from PubMed, the FDA, or peer-reviewed clinical trials — never blog summaries or marketing pages. Articles are reviewed and revised whenever the underlying evidence base changes.
We do not sell or recommend specific medical treatments — talk to a licensed clinician before starting any medication. Read our full methodology →